Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
- Authors:
- Xiao Hu
- Jin Ren
- Qianfei Xue
- Rumei Luan
- Dongyan Ding
- Jie Tan
- Xin Su
- Junling Yang
-
Affiliations: Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China, Department of Respiratory Medicine, Hospital of Jilin University, Changchun, Jilin 130012, P.R. China - Published online on: September 6, 2023 https://doi.org/10.3892/ijo.2023.5570
- Article Number: 122
-
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, et al: Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab. Oncologist. 23:1358–1365. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ozkaya S, Findik S, Dirican A and Atici AG: Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med. 4:1035–1038. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, et al: Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 study. J Clin Oncol. 37:2518–2527. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, et al: Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 35:709–717. 2017. View Article : Google Scholar | |
|
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet. 389:255–265. 2017. View Article : Google Scholar | |
|
Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, et al: Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: The lung-MAP S1400I phase 3 randomized clinical trial. JAMA Oncol. 7:1368–1377. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Boyer M, Şendur MAN, Rodríguez-Abreu D, Park K, Lee DH, Çiçin I, Yumuk PF, Orlandi FJ, Leal TA, Molinier O, et al: Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥50%: Randomized, double-blind phase III KEYNOTE-598 study. J Clin Oncol. 39:2327–2338. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, et al: Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: The MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 6:661–674. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, et al: Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial. Nat Med. 27:504–514. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Khoja L, Day D, Wei-Wu Chen T, Siu LL and Hansen AR: Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review. Ann Oncol. 28:2377–2385. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen K and Sun B: Incidence and risk of PD-1/PD-L1 inhibitor-associated pneumonia in advance cancer patients: A meta-analysis. Zhongguo Fei Ai Za Zhi. 23:927–940. 2020.In Chinese. PubMed/NCBI | |
|
Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Hanai N, Muro K and Hida T: Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: A retrospective analysis. BMC Cancer. 21:9242021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol. 4:1721–1728. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH and Hodi FS: Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis. JAMA Oncol. 2:1607–1616. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hahn AW, Gill DM, Agarwal N and Maughan BL: PD-1 checkpoint inhibition: Toxicities and management. Urol Oncol. 35:701–707. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applica-tions/docs/CTCAE_v5_Quick_Reference_5x7.pdf. | |
|
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, et al: Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 15:816–826. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Zhang T, Huang Y, Li W, Zhao J, Yang Y, Li C, Wang L and Bi N: Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: A systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 112:1154–1164. 2022. View Article : Google Scholar | |
|
Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N and Hasegawa Y: Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors. Clin Lung Cancer. 20:442–450.e4. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shibaki R, Murakami S, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Kusumoto M, et al: Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol Immunother. 69:15–22. 2020. View Article : Google Scholar | |
|
Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Yokoi T, Asao T, Tamiya M, Nakamura A, et al: Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. Eur J Cancer. 150:63–72. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ono K, Ono H, Toi Y, Sugisaka J, Aso M, Saito R, Kawana S, Aiba T, Odaka T, Matsuda S, et al: Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer. Cancer Med. 10:4796–4804. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chu X, Zhao J, Zhou J, Zhou F, Jiang T, Jiang S, Sun X, You X, Wu F, Ren S, et al: Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Lung Cancer. 150:76–82. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cui P, Huang D, Wu Z, Tao H, Zhang S, Ma J, Liu Z, Wang J, Huang Z, Chen S, et al: Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer. Ther Adv Med Oncol. 12:17588359209220332020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J, et al: Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis. BMC Cancer. 21:6342021. View Article : Google Scholar : PubMed/NCBI | |
|
Yamagata A, Yokoyama T, Fukuda Y and Ishida T: Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. 87:251–258. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chao Y, Zhou J, Hsu S, Ding N, Li J, Zhang Y, Xu X, Tang X, Wei T, Zhu Z, et al: Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. Transl Lung Cancer Res. 11:295–306. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, et al: Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol. 13:1930–1939. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cho JY, Kim J, Lee JS, Kim YJ, Kim SH, Lee YJ, Cho YJ, Yoon HI, Lee JH, Lee CT and Park JS: Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer. 125:150–156. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Y, Shao C, Li S, Xu Y, Xu K, Zhang Y, Huang H, Wang M and Xu Z: Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. Asia Pac J Clin Oncol. 16:299–304. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Tang L, Zhou Y, He W and Li W: Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: Current understanding in characteristics, diagnosis, and management. Front Immunol. 12:6639862021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C, Gao F, Jin S, Gao W, Chen S and Guo R: Checkpoint inhibitor pneumonitis in Chinese lung cancer patients: Clinical characteristics and risk factors. Ann Palliat Med. 9:3957–3965. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, et al: Distinct immunophenotypes of T cells in bronchoalveolar lavage fluid from leukemia patients with immune checkpoint inhibitors-related pulmonary complications. Front Immunol. 11:5904942021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Zhao Y, Zhang X, Si X, Song P, Xiao Y, Yang X, Song L, Shi J, Zhao H and Zhang L: Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. Cancer Med. 10:188–198. 2021. View Article : Google Scholar | |
|
Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF and Hodi FS: PD-1 inhibitor-related pneumonitis in advanced cancer patients: Radiographic patterns and clinical course. Clin Cancer Res. 22:6051–6060. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tone M, Izumo T, Awano N, Kuse N, Inomata M, Jo T, Yoshimura H, Minami J, Takada K, Miyamoto S and Kunitoh H: High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. Thorac Cancer. 10:2006–2012. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Suresh K, Naidoo J, Lin CT and Danoff S: Immune checkpoint immunotherapy for non-small cell lung cancer: Benefits and pulmonary toxicities. Chest. 154:1416–1423. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ribas A and Wolchok JD: Cancer immunotherapy using checkpoint blockade. Science. 359:1350–1355. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Schildberg FA, Klein SR, Freeman GJ and Sharpe AH: Coinhibitory pathways in the B7‑CD28 ligand‑receptor family. Immunity. 44:955–972. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, et al: Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science. 332:600–603. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Baumeister SH, Freeman GJ, Dranoff G and Sharpe AH: Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 34:539–573. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kang SP, Gergich K, Lubiniecki GM, de Alwis DP, Chen C, Tice MAB and Rubin EH: Pembrolizumab KEYNOTE-001: An adaptive study leading to accelerated approval for two indications and a companion diagnostic. Ann Oncol. 28:1388–1398. 2017. View Article : Google Scholar : | |
|
Suresh K, Naidoo J, Zhong Q, Xiong Y, Mammen J, de Flores MV, Cappelli L, Balaji A, Palmer T, Forde PM, et al: The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Invest. 129:4305–4315. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Läubli H, Koelzer VH, Matter MS, Herzig P, Dolder Schlienger B, Wiese MN, Lardinois D, Mertz KD and Zippelius A: The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology. 7:e13863622017. View Article : Google Scholar | |
|
Rowshanravan B, Halliday N and Sansom DM: CTLA-4: A moving target in immunotherapy. Blood. 131:58–67. 2018. View Article : Google Scholar | |
|
Naidoo J, Cottrell TR, Lipson EJ, Forde PM, Illei PB, Yarmus LB, Voong KR, Feller-Kopman D, Lee H, Riemer J, et al: Chronic immune checkpoint inhibitor pneumonitis. J Immunother Cancer. 8:e0008402020. View Article : Google Scholar : PubMed/NCBI | |
|
Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, et al: Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci USA. 113:11919–11924. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ivanova EA and Orekhov AN: T helper lymphocyte subsets and plasticity in autoimmunity and cancer: An overview. Biomed Res Int. 2015:3274702015. View Article : Google Scholar : PubMed/NCBI | |
|
Lee J, Lozano-Ruiz B, Yang FM, Fan DD, Shen L and González-Navajas JM: The multifaceted role of Th1, Th9, and Th17 cells in immune checkpoint inhibition therapy. Front Immunol. 12:6256672021. View Article : Google Scholar : PubMed/NCBI | |
|
Dejima H, Hu X, Chen R, Zhang J, Fujimoto J, Parra ER, Haymaker C, Hubert SM, Duose D, Solis LM, et al: Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun. 12:27222021. View Article : Google Scholar : PubMed/NCBI | |
|
Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, Gorecka MA, de Haan AF, Mulders P, Punt CJ, et al: PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 35:169–178. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshino K, Nakayama T, Ito A, Sato E and Kitano S: Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: Two case reports. BMC Cancer. 19:10192019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang YN, Lou DF, Li DY, Jiang W, Dong JY, Gao W and Chen HC: Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Oncol Lett. 20:611–622. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Passat T, Touchefeu Y, Gervois N, Jarry A, Bossard C and Bennouna J: Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment. Bull Cancer. 105:1033–1041. 2018.In French. View Article : Google Scholar : PubMed/NCBI | |
|
Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW and Dong C: T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 31:787–798. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Franken A, Van Mol P, Vanmassenhove S, Donders E, Schepers R, Van Brussel T, Dooms C, Yserbyt J, De Crem N, Testelmans D, et al: Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis. J Immunother Cancer. 10:e0053232022. View Article : Google Scholar : PubMed/NCBI | |
|
Gianchecchi E and Fierabracci A: Inhibitory receptors and pathways of lymphocytes: The role of PD-1 in treg development and their involvement in autoimmunity onset and cancer progression. Front Immunol. 9:23742018. View Article : Google Scholar : PubMed/NCBI | |
|
D'Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF, Pipeling MR, Brower RG, Tuder RM, McDyer JF and King LS: CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest. 119:2898–2913. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lin X, Deng J, Deng H, Yang Y, Sun N, Zhou M, Qin Y, Xie X, Li S, Zhong N, et al: Comprehensive analysis of the immune microenvironment in checkpoint inhibitor pneumonitis. Front Immunol. 12:8184922022. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Jia X, Du Y, Mao Z, Zhang Y, Shen Y, Sun H, Liu M, Niu G, Wang J, et al: Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis. Front Oncol. 12:8271992022. View Article : Google Scholar : PubMed/NCBI | |
|
Kowalski B, Valaperti A, Bezel P, Steiner UC, Scholtze D, Wieser S, Vonow-Eisenring M, Widmer A, Kohler M and Franzen D: Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: A cross-sectional case-control study. J Cancer Res Clin Oncol. 148:1711–1720. 2022. View Article : Google Scholar | |
|
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, et al: Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): Interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 23:209–219. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, Breen EJ, Yang JYH, Ghazanfar S, Kefford RF, et al: Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res. 25:1557–1563. 2019. View Article : Google Scholar | |
|
Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, et al: New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 20:e54–e64. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hunter CA and Jones SA: IL-6 as a keystone cytokine in health and disease. Nat Immunol. 16:448–457. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Scheller J, Chalaris A, Schmidt-Arras D and Rose-John S: The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 1813:878–888. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lin X, Deng H, Yang Y, Wu J, Qiu G, Li S, Xie X, Liu M, Xie Z, Qin Y, et al: Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer. Front Oncol. 11:6988322021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou C, Yang Y, Lin X, Fang N, Chen L, Jiang J, Deng H, Deng Y, Wan M, Qiu G, et al: Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis. Front Immunol. 13:9357792022. View Article : Google Scholar : PubMed/NCBI | |
|
Iwanaga N and Kolls JK: Updates on T helper type 17 immunity in respiratory disease. Immunology. 156:3–8. 2019. View Article : Google Scholar | |
|
Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG, Wang XX, Liu HZ, Sun W and Hu ZW: Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol. 187:3003–3014. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Miossec P and Kolls JK: Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 11:763–776. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
McAlees JW, Lajoie S, Dienger K, Sproles AA, Richgels PK, Yang Y, Khodoun M, Azuma M, Yagita H, Fulkerson PC, et al: Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma. Eur J Immunol. 45:1019–1029. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH and Kirkwood JM: Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 3:392015. View Article : Google Scholar | |
|
Kolb M, Margetts PJ, Anthony DC, Pitossi F and Gauldie J: Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest. 107:1529–1536. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z and He J: Infliximab in the treatment of tislelizumab-induced steroid-refractory immune checkpoint inhibitor-related pneumonia: Case report and literature review. Transl Cancer Res. 11:3309–3314. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Shamskhou EA, Kratochvil MJ, Orcholski ME, Nagy N, Kaber G, Steen E, Balaji S, Yuan K, Keswani S, Danielson B, et al: Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice. Biomaterials. 203:52–62. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Osuna-Gómez R, Barril S, Mulet M, Zamora Atenza C, Millan-Billi P, Pardessus A, Brough DE, Sabzevari H, Semnani RT, Castillo D and Vidal S: The immunoregulatory role of IL-35 in patients with interstitial lung disease. Immunology. 168:610–621. 2023. View Article : Google Scholar | |
|
de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H and de Vries JE: Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 174:915–924. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Okada K, Fujimura T, Kikuchi T, Aino M, Kamiya Y, Izawa A, Iwamura Y, Goto H, Okabe I, Miyake E, et al: Effect of interleukin (IL)-35 on IL-17 expression and production by human CD4+ T cells. PeerJ. 5:e29992017. View Article : Google Scholar | |
|
Wang HM, Zhang XH, Feng MM, Qiao YJ, Ye LQ, Chen J, Fan FF and Guo LL: Interleukin-35 suppresses the antitumor activity of T cells in patients with non-small cell lung cancer. Cell Physiol Biochem. 47:2407–2419. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Castellani ML, Anogeianaki A, Felaco P, Toniato E, De Lutiis MA, Shaik B, Fulcheri M, Vecchiet J, Tetè S, Salini V, et al: IL-35, an anti-inflammatory cytokine which expands CD4+CD25+ Treg cells. J Biol Regul Homeost Agents. 24:131–135. 2010.PubMed/NCBI | |
|
Wang H, Zhou F, Zhao C, Cheng L, Zhou C, Qiao M, Li X and Chen X: Interleukin-10 is a promising marker for immune-related adverse events in patients with non-small cell lung cancer receiving immunotherapy. Front Immunol. 13:8403132022. View Article : Google Scholar : PubMed/NCBI | |
|
Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, et al: Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 5:376–383. 2019. View Article : Google Scholar | |
|
Zhou J, Zhao J, Jia Q, Chu Q, Zhou F, Chu X, Zhao W, Ren S, Zhou C and Su C: Peripheral blood autoantibodies against to tumor-associated antigen predict clinical outcome to immune checkpoint inhibitor-based treatment in advanced non-small cell lung cancer. Front Oncol. 11:6255782021. View Article : Google Scholar : PubMed/NCBI | |
|
Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, et al: Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci USA. 116:22246–22251. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, et al: Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 28:1368–1379. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y and Hida T: Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis. Lung Cancer. 125:212–217. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K, Yoshida H, Akai M, Mio T and Hirai T: Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer. 9:847–855. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Fan Y, Nie L, Wang G, Sun K and Cheng Y: Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: A systematic review and meta-analysis. Chest. 161:1675–1686. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Tasaka Y, Honda T, Nishiyama N, Tsutsui T, Saito H, Watabe H, Shimaya K, Mochizuki A, Tsuyuki S, Kawahara T, et al: Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. Lung Cancer. 155:120–126. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Fujimoto D, Yomota M, Sekine A, Morita M, Morimoto T, Hosomi Y, Ogura T, Tomioka H and Tomii K: Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial. Lung Cancer. 134:274–278. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaguchi O, Kaira K, Shinomiya S, Mouri A, Hashimoto K, Shiono A, Miura Y, Akagami T, Imai H, Kobayashi K and Kagamu H: Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab. Thorac Cancer. 12:304–313. 2021. View Article : Google Scholar | |
|
Lu Y, Zhong W, Liu Y, Chen W, Zhang J, Zeng Z, Huang H, Qiao Y, Wan X, Meng X, et al: Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway. Int Immunopharmacol. 104:1085042022. View Article : Google Scholar : PubMed/NCBI | |
|
Sul J, Blumenthal GM, Jiang X, He K, Keegan P and Pazdur R: FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist. 21:643–650. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhai X, Zhang J, Tian Y, Li J, Jing W, Guo H and Zhu H: The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biol Med. 17:599–611. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Galant-Swafford J, Troesch A, Tran L, Weaver A, Doherty TA and Patel SP: Landscape of immune-related pneumonitis in cancer patients with asthma being treated with immune checkpoint blockade. Oncology. 98:123–130. 2020. View Article : Google Scholar | |
|
Barrón F, Sánchez R, Arroyo-Hernández M, Blanco C, Zatarain-Barrón ZL, Catalán R, Ramos-Ramírez M, Cardona AF, Flores-Estrada D and Arrieta O: Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy. Front Oncol. 10:5702332020. View Article : Google Scholar : PubMed/NCBI | |
|
Cui P, Liu Z, Wang G, Ma J, Qian Y, Zhang F, Han C, Long Y, Li Y, Zheng X, et al: Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: A case-control study. Cancer Med. 7:4115–4120. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB and Lee P: Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 18:895–903. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Voong KR, Hazell SZ, Fu W, Hu C, Lin CT, Ding K, Suresh K, Hayman J, Hales RK, Alfaifi S, et al: Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 20:e470–e479. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lin GF, Xu Y, Lin H, Yang DY, Chen L, Huang LL, Su XS, Xu YX and Zeng YM: The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials. Int Immunopharmacol. 99:1080112021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang M, Liang H, Wang W, Zhao S, Cai X, Zhao Y, Li C, Cheng B, Xiong S, Li J, et al: Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials. Cancer. 127:777–786. 2021. View Article : Google Scholar | |
|
Matsuo N, Azuma K, Kojima T, Ishii H, Tokito T, Yamada K and Hoshino T: Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy. Invest New Drugs. 39:1150–1158. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Oshima Y, Tanimoto T, Yuji K and Tojo A: EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 4:1112–1115. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Oxnard GR, Yang JCH, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, et al: TATTON: A multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 31:507–516. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA and Velcheti V: Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. Chest. 152:271–281. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Balasubramanian A, Onggo J, Gunjur A, John T and Parakh S: Immune checkpoint inhibition with chemoradiotherapy in stage III non-small-cell lung cancer: A systematic review and meta-analysis of safety results. Clin Lung Cancer. 22:74–82. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Gomatou G, Tzilas V, Kotteas E, Syrigos K and Bouros D: Immune checkpoint inhibitor-related pneumonitis. Respiration. 99:932–942. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Spakowicz D, Zhao S, Patel SH, Johns A, Grogan M, Miah A, Husain M, He K, Bertino EM, et al: Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunol Immunother. 69:2403–2408. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou P, Zhao X and Wang G: Risk factors for immune checkpoint inhibitor-related pneumonitis in cancer patients: A systemic review and meta-analysis. Respiration. 101:1035–1050. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Sawa K, Sato I, Takeuchi M and Kawakami K: Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: A nationwide retrospective cohort study. Cancer Immunol Immunother. 72:591–598. 2023. View Article : Google Scholar | |
|
Suresh K, Psoter KJ, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, et al: Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol. 14:494–502. 2019. View Article : Google Scholar | |
|
Reuss JE, Brigham E, Psoter KJ, Voong KR, Shankar B, Ettinger DS, Marrone KA, Hann CL, Levy B, Feliciano JL, et al: Pretreatment lung function and checkpoint inhibitor pneumonitis in NSCLC. JTO Clin Res Rep. 2:1002202021.PubMed/NCBI | |
|
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, et al: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 36:1714–1768. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S and Larkin J: Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28(Suppl 4): iv119–iv142. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Puzanov I, Diab A, Abdallah K, Bingham CO III, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al: Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 5:952017. View Article : Google Scholar : PubMed/NCBI | |
|
Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, Cherukuri S, Parent T, Hardin J and Walker P: Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 25:551–557. 2019. View Article : Google Scholar | |
|
Karayama M, Inui N, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Asada K, et al: Six-week oral prednisolone therapy for immune-related pneumonitis: A single-arm phase II study. J Immunother Cancer. 11:e0070562023. View Article : Google Scholar : PubMed/NCBI | |
|
Luo J, Beattie JA, Fuentes P, Rizvi H, Egger JV, Kern JA, Leung DYM, Lacouture ME, Kris MG, Gambarin M, et al: Beyond steroids: Immunosuppressants in steroid-refractory or resistant immune-related adverse events. J Thorac Oncol. 16:1759–1764. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Balaji A, Hsu M, Lin CT, Feliciano J, Marrone K, Brahmer JR, Forde PM, Hann C, Zheng L, Lee V, et al: Steroid-refractory PD-(L)1 pneumonitis: Incidence, clinical features, treatment, and outcomes. J Immunother Cancer. 9:e0017312021. View Article : Google Scholar : PubMed/NCBI | |
|
Beattie J, Rizvi H, Fuentes P, Luo J, Schoenfeld A, Lin IH, Postow M, Callahan M, Voss MH, Shah NJ, et al: Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. J Immunother Cancer. 9:e0018842021. View Article : Google Scholar : PubMed/NCBI | |
|
Camard M, Besse B, Cariou PL, Massayke S, Laparra A, Noel N, Michot JM, Ammari S, Pavec JL and Lambotte O: Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors. Respir Med Res. 82:1009692022.PubMed/NCBI | |
|
Xie XH, Deng HY, Lin XQ, Wu JH, Liu M, Xie ZH, Qin YY and Zhou CZ: Case report: Nintedanib for pembrolizumab-related pneumonitis in a patient with non-small cell lung cancer. Front Oncol. 11:6738772021. View Article : Google Scholar : PubMed/NCBI | |
|
Gu J, Shi L, Jiang X, Wen J, Zheng X, Cai H and Zhang W: Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: A network meta-analysis of randomized clinical trials. Cancer Immunol Immunother. 71:2239–2254. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, et al: Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 40:509–523.e6. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Renga G, Bellet MM, Pariano M, Gargaro M, Stincardini C, D'Onofrio F, Mosci P, Brancorsini S, Bartoli A, Goldstein AL, et al: Thymosin α1 protects from CTLA-4 intestinal immunopathology. Life Sci Alliance. 3:e2020006622020. View Article : Google Scholar | |
|
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, et al: First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 376:2415–2426. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et al: Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 379:2040–2051. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, et al: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, et al: Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 15:1636–1646. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, Zhang L, Huang D, Cang S, Yang Z, et al: Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 16:1501–1511. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, et al: Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): A randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 9:305–314. 2021. View Article : Google Scholar | |
|
Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov O, et al: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 397:592–604. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, et al: Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 383:1328–1339. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S, Orlandi F, et al: Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results From the randomized phase 3 IMpower132 trial. J Thorac Oncol. 16:653–664. 2021. View Article : Google Scholar | |
|
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, et al: Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): Interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 23:220–233. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 387:1540–1550. 2016. View Article : Google Scholar | |
|
Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu HY, Wu L, Feng J, et al: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol. 14:867–875. 2019. View Article : Google Scholar : PubMed/NCBI |
